Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Quick Listen: Scrip's Five Must-Know Things

Executive Summary

In this week's podcast version of Five Must-Know Things: Novo obesity drugs in US cost-effectiveness spotlight; Biogen’s growth challenges; Novartis’s view on large M&A; pharma’s Q2 outlook; and MSD on Lagevrio.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 22 July 2022, including: Novo Nordisk A/S obesity drugs in US cost-effectiveness spotlight; Biogen, Inc.’s growth challenges; Novartis AG’s view on large M&A; pharma’s Q2 outlook; and MSD on Lagevrio.

This and all our other podcasts are available on the Pharma Intelligence channel on Apple PodcastsGoogle PodcastsSoundCloudTuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.  

Stories mentioned in this episode:

(Also see "Novo Nordisk's Obesity Drugs Exceed ICER’s Cost Effectiveness Thresholds" - Scrip, 18 Jul, 2022.)

(Also see "Without An Alzheimer’s Blockbuster, Biogen Is A Ship Without A Growth Rudder" - Scrip, 20 Jul, 2022.)

(Also see "Novartis Finance Chief Rules Out Large M&A" - Scrip, 19 Jul, 2022.)

(Also see "Pharma Q2 Preview: Demonstrating Resiliency Against A Turbulent Backdrop" - Scrip, 15 Jul, 2022.)

(Also see "MSD’s Asia Pacific Chief On Lagevrio’s Gains In Clinical Utility Amid Paxlovid Luster" - Scrip, 19 Jul, 2022.)

 

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146762

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel